12 / 21
Page 65
Notes:
Volume 3, Issue 4 (Suppl)
J Clin Exp Orthop
ISSN:2471-8416
Osteoporosis and Arthroplasty 2017
December 04-05, 2017
&
11
th
International Conference on
Joint Event
OSTEOPOROSIS, ARTHRITIS & MUSCULOSKELETAL DISORDERS
December 04-05, 2017 | Madrid, Spain
10
th
INTERNATIONAL CONFERENCE ON ARTHROPLASTY
Gauri Billa et al., J Clin Exp Orthop 2017, 3:4(Suppl)
DOI: 10.4172/2471-8416-C1-003
Medical management practices in patients with clinically apparent osteoporotic fragility fracture – In
Indian setting
Gauri Billa
1
, Arvind Bhave
2
, Shreedhar Archik
3
, Milind Modak
4
, Tejas Upasani
5
and
Zubair Sorathia
6
1
Abbott Healthcare Pvt. Ltd, India
2
Bhave Hospital, India
3
Care Clinic, India
4
Yogesh Hospital, India
5
Upasani Maternity & Surgical Nursing Home, India
6
Medicare Hospital, India
O
steoporosis poses a huge challenge in India, with reported prevalence rates varying from 8% to 62% in Indian women. Despite
high prevalence, data is scarce on the current management practices followed in Indian patients with clinically apparent
osteoporotic fragility fracture. Hence this pan India study was conducted to understand the demographics, patient characteristics,
contributing risk factors, management practices and the effect of teriparatide treatment on procollagen type-I N-terminal propeptide
(P1NP) bio-response marker (change in PINP at 3 months from baseline) in these patients, in Indian real-world setting. Adults (≥50
years) with fragility fracture, on anti-osteoporotic treatment (excluding calcium/vitamin D), were enrolled. A total of 62 (30.69%)
out of 202 enrolled patients completed the 12-month follow-up; 140 (69.31%) patients were lost to follow-up. Mean age of the study
population was 67.48±9.34 years (women: 87.62%). Major sites of fracture were hip (10.9%), wrist (21.3%) and vertebra (69.8%). Most
commonly (≥25%) identified environmental/medical risk factors were poor balance (34.57%), lack of assistive devices in bathrooms
(32.10%), previous fall (28.40%) and obstacles in the walking path (27.16%). Most commonly prescribed anti-osteoporotic treatment
post-fragility fracture were ibandronic acid (23.76%); zoledronic acid (21.78%), teriparatide (20.79%), calcium (12.87%), risedronate
sodium (9.41%) and vitamin D (8.42%). Mean (SD) change in P1NP at 3 months from baseline was ˃10 mcg/L (10.76±77.27 mcg/L)
in subjects on teriparatide. This study sheds light on the current management practices among Indian orthopedic surgeons for treating
patients with clinically apparent osteoporotic fragility fracture. Increase in PINP >10 mcg/L post teriparatide therapy provides an
earlier confirmation of anabolic effect, which in turn may be a useful aid for the management of osteoporosis. Further, a large
proportion of patients were lost to follow-up, indicating the need for increasing awareness among patients, for a successful long-term
therapy.
Biography
Gauri Billa is an experienced Senior Medical Advisor with a demonstrated history of working in the hospital & health care industry. She has excellent skills in Clinical
Research, Pharmacology, Clinical Trials, Healthcare, and Clinical Pharmacology. She is a strong healthcare services professional with a Doctor of Medicine (M.D.)
focused in Pharmacology from King Edward Memorial Hsopital.
shalini.nair@abbott.com